Furthermore, ARHGAP39 potentially regulated the immune-related pathways, and affected the tumor-infiltrating immune cells, thus providing opportunities for the development of novel immunotherapies for breast cancer treatment. Here, ARHGAP39 is linked to breast carcinoma.